Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7851960 | 1.00 | ALDH1A1 (0.53) | ALDH1A1NOS1NOS2SLC18A3 | |
| SCHEMBL7845038 | 1.00 | ALDH1A1 (0.53) | ALDH1A1NOS1NOS2SLC18A3 | |
| SCHEMBL10672870 | 0.97 | ALDH1A1 (0.57) | ALDH1A1 | |
| SCHEMBL2105103 | 0.97 | ALDH1A1 (0.57) | ALDH1A1 | |
| SCHEMBL2105322 | 0.90 | ALDH1A1 (0.47) | ALDH1A1 | |
| SCHEMBL9821061 | 0.90 | ALDH1A1 (0.47) | ALDH1A1 | |
| SCHEMBL743899 | 0.86 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL7853346 | 0.85 | ALDH1A1 (0.44) | ALDH1A1NOS1NOS2 | |
| SCHEMBL1366434 | 0.85 | ALDH1A1 (0.44) | ALDH1A1NOS1NOS2 | |
| SCHEMBL7856162 | 0.85 | ALDH1A1 (0.44) | ALDH1A1NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569588-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2009-08-04 | — | — | US | claimed |
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | claimed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | claimed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | claimed |
| US-20050203083-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2005-09-15 | — | — | US | claimed |
| JP-2001509484-A | — | — | 2001-07-24 | — | — | JP | claimed |
| EP-0994712-A1 | INHIBITORS OF NEUTROPHIL MEDIATED OXIDANT PRODUCTION | ELI LILLY AND COMPANY (US) | 2000-04-26 | — | — | EP | claimed |
| WO-1999002163-A1 | INHIBITORS OF NEUTROPHIL MEDIATED OXIDANT PRODUCTION | ELI LILLY AND COMPANY (US) | 1999-01-21 | — | — | WO | claimed |
| US-20160376240-A1 | 6 Phenyl or 6 Pyridin 3 YL Indazole Derivatives and Methods of Use | ABBVIE INC. (US) | 2016-12-29 | — | — | US | disclosed |
| EP-3097091-A1 | 6-PHENYL- OR 6-(PYRIDIN-3-YL)INDAZOLE DERIVATIVES AND METHODS OF USE | AbbVie Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| WO-2015112445-A1 | 6-PHENYL- OR 6-(PYRIDIN-3-YL)INDAZOLE DERIVATIVES AND METHODS OF USE | ABBVIE INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| EP-1819667-B1 | SULFONAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY INC (US) | 2012-10-17 | — | — | EP | disclosed |
| US-8163735-B2 | Sulfonamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-7858792-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-5643925-A | COGNITION ACTIVATORS AND NERVE GROWTH FACTORS | SANKYO COMPANY, LIMITED (JP) | 1997-07-01 | — | — | US | disclosed |
| US-5614521-A | NERVE GROWTH FACTOR | SANKYO COMPANY, LIMITED (JP) | 1997-03-25 | — | — | US | disclosed |
| EP-0719258-A1 | CYCLIC AMIDE DERIVATIVES FOR PROTECTING AGAINST ULTRAVIOLET RAYS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-07-03 | — | — | EP | disclosed |
| WO-1996002508-A1 | CYCLIC AMIDE DERIVATIVES FOR PROTECTING AGAINST ULTRAVIOLET RAYS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-02-01 | — | — | WO | disclosed |
| EP-0561639-A1 | Cyclic peptide antifungal agents and process for preparation thereof | ELI LILLY AND COMPANY (US) | 1993-09-22 | — | — | EP | disclosed |
| EP-0501656-A2 | New benzene derivatives having (NGF) production-promoting activity | Sankyo Company Limited (JP) | 1992-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | ALDH1A1 1731/4885NOS1 398/4885NOS2 350/4885 |
| US-20160376240-A1 | 6 Phenyl or 6 Pyridin 3 YL Indazole Derivatives and Methods of Use | MUSK, NTRK3, NTRK2 | ALDH1A1 3074/4885NOS1 3758/4885NOS2 3520/4885 |
| US-20050203083-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM1, CHRM3 | ALDH1A1 1670/4885NOS1 3292/4885NOS2 3908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.